Daily phone surveys to track the real-life burden of hereditary angioedema

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project asks adults with confirmed HAE to complete brief digital surveys each day for eight consecutive weeks using the m-Path app, plus standardized questionnaires. The approach uses ecological momentary assessment (EMA) to capture symptoms, mood, and perceived burden in real time rather than relying on memory-based reports. Researchers hypothesize EMA will show greater and more fluctuating burden than retrospective scales and better reflect everyday impact. No experimental treatments are given; the focus is on measurement and understanding patient experience.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed diagnosis of Type 1 or Type 2 hereditary angioedema;
* Age ≥ 18 years;
* Ability to understand instructions and provide informed consent;
* Ownership and proficiency in using a personal smartphone compatible with the m-Path application (Android or iOS);
* Willingness to participate in the study for the entire duration of the observation period (8 weeks).

Exclusion Criteria:

* Diagnosis of acquired angioedema or other forms of angioedema unrelated to C1-inhibitor deficiency;
* Severe cognitive or psychiatric disorders that compromise the ability to complete the questionnaires independently;
* Age \< 18 years;

Where it's running

• Istituti Clinici Scientifici Maugeri, Milan, Milan 20138
  Milan, Italy Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term treatment with ADX-324 for people with hereditary angioedema

  This extension will try additional doses of ADX-324 (onvuzosiran) to see if continuing the drug is safe and helps people with Type I or II hereditary angioedema who finished the earlier Phase 3 trial.

  Recruiting at 3 sites Phase 3 ADARx Pharmaceuticals, Inc. · Litchfield Park, Arizona and 47 other locations · NCT07428499

• STOP-HAE: ADX-324 for hereditary angioedema

  This trial tests whether ADX-324 can reduce HAE attacks in adults with Type 1 or Type 2 hereditary angioedema.

  Recruiting at 52 sites Phase 3 ADARx Pharmaceuticals, Inc. · Litchfield Park, Arizona and 69 other locations · NCT06960213

• Takhzyro use in teenagers and adults with hereditary angioedema in South Korea

  This study looks at how safe and useful Takhzyro is when used in real-world care for teenagers and adults with hereditary angioedema in South Korea.

  Recruiting at 3 sites Takeda · Suwon, Gyeonggi-do and 2 other locations · NCT07445087

• Donidalorsen for children with hereditary angioedema

  This trial tests if donidalorsen is safe and how it is processed in the body for children aged 2 to under 12 with hereditary angioedema types I or II.

  Recruiting at 18 sites Phase 3 Ionis Pharmaceuticals, Inc. · Santa Monica, California and 17 other locations · NCT07298447

• C1-Inhibitor Function Test to Diagnose HAE in Algeria

  A test that measures C1-inhibitor function is being tried to see if it can accurately diagnose hereditary angioedema in patients in Algeria.

  Recruiting Takeda · Algiers · NCT07293364

• Oral deucrictibant to prevent and treat hereditary angioedema attacks

  This trial tests whether daily oral deucrictibant XR can prevent angioedema attacks and whether deucrictibant capsules can quickly relieve acute attacks in adults with bradykinin-mediated hereditary angioedema.

  Recruiting Phase 1/2 Institute for Asthma and Allergy · Wheaton, Maryland · NCT07046806

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.